- Home
- SONN vs APVO Comparison
SONN vs APVO Comparison
Compare SONN & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SONN
- APVO
- Stock Information
- Founded
- SONN N/A
- APVO 2016
- Country
- SONN United States
- APVO United States
- Employees
- SONN N/A
- APVO N/A
- Industry
- SONN Biotechnology: Pharmaceutical Preparations
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- SONN Health Care
- APVO Health Care
- Exchange
- SONN Nasdaq
- APVO Nasdaq
- Market Cap
- SONN 3.8M
- APVO 4.1M
- IPO Year
- SONN N/A
- APVO N/A
- Fundamental
- Price
- SONN $3.54
- APVO $2.00
- Analyst Decision
- SONN Strong Buy
- APVO Strong Buy
- Analyst Count
- SONN 1
- APVO 1
- Target Price
- SONN $20.00
- APVO $5,920.00
- AVG Volume (30 Days)
- SONN 934.4K
- APVO 134.2K
- Earning Date
- SONN 08-26-2025
- APVO 08-11-2025
- Dividend Yield
- SONN N/A
- APVO N/A
- EPS Growth
- SONN N/A
- APVO N/A
- EPS
- SONN N/A
- APVO N/A
- Revenue
- SONN $1,000,000.00
- APVO N/A
- Revenue This Year
- SONN $5,376.22
- APVO N/A
- Revenue Next Year
- SONN N/A
- APVO N/A
- P/E Ratio
- SONN N/A
- APVO N/A
- Revenue Growth
- SONN 978.39
- APVO N/A
- 52 Week Low
- SONN $1.08
- APVO $1.72
- 52 Week High
- SONN $19.30
- APVO $381.10
- Technical
- Relative Strength Index (RSI)
- SONN 48.94
- APVO 29.31
- Support Level
- SONN $2.80
- APVO $1.72
- Resistance Level
- SONN $4.29
- APVO $2.20
- Average True Range (ATR)
- SONN 0.55
- APVO 0.18
- MACD
- SONN -0.02
- APVO 0.01
- Stochastic Oscillator
- SONN 58.56
- APVO 22.58
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.